title: [Improvement of sensitivity in the second generation HCV core antigen assay by a novel concentration method using polyethylene glycol (PEG)].
abstract: A HCV core antigen (Ag) detection assay system, Lumipulse Ortho HCV Ag has been developed and is commercially available in Japan with a lower detection level limit of 50 fmol/l, which is equivalent to 20 KIU/ml in PCR quantitative assay. HCV core Ag assay has an advantage of broader dynamic range compared with PCR assay, however the sensitivity is lower than PCR. We developed a novel HCV core Ag concentration method using polyethylene glycol (PEG), which can improve the sensitivity five times better than the original assay. The reproducibility was examined by consecutive five-time measurement of HCV patients serum, in which the results of HCV core Ag original and concentrated method were 56.8 +/- 8.1 fmol/l (mean +/- SD), CV 14.2% and 322.9 +/- 45.5 fmol/l CV 14.0%, respectively. The assay results of HCV negative samples in original HCV core Ag were all 0.1 fmol/l and the results were same even in the concentration method. The results of concentration method were 5.7 times higher than original assay, which was almost equal to theoretical rate as expected. The assay results of serially diluted samples were also as same as expected data in both original and concentration assay. We confirmed that the sensitivity of HCV core Ag concentration method had almost as same sensitivity as PCR high range assay in the competitive assay study using the serially monitored samples of five HCV patients during interferon therapy. A novel concentration method using PEG in HCV core Ag assay system seems to be useful for assessing and monitoring interferon treatment for HCV.
authors.affiliation: Clinical Laboratory, Tokyo Metropolitan Hiroo Hospital, Shibuya-ku, Tokyo.
authors.forename: Makiko
authors.initials: M
authors.lastname: Higashimoto
authors.forename: Masahiko
authors.initials: M
authors.lastname: Takahashi
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Jokyu
authors.forename: Hiromi
authors.initials: H
authors.lastname: Syundou
authors.forename: Hidetsugu
authors.initials: H
authors.lastname: Saito
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D006526:Hepatitis C / Q000175:diagnosis* / Q000188:drug therapy; D018936:Hepatitis C Antigens / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D016898:Interferon-alpha / Q000627:therapeutic use; D008163:Luminescent Measurements / Q000379:methods*; D011092:Polyethylene Glycols; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood; D012680:Sensitivity and Specificity; D014758:Viral Core Proteins / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D018936:Hepatitis C Antigens; D016898:Interferon-alpha; D012367:RNA, Viral; D014758:Viral Core Proteins; D011092:Polyethylene Glycols